MiMedx Group

MiMedx Group a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The Company’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

Company Growth (employees)
Marietta, US
Size (employees)
690 (est)
MiMedx Group was founded in 2008 and is headquartered in Marietta, US

Key People/Management at MiMedx Group

Parker H. Petit

Parker H. Petit

CEO & Chairman
Frank Burrows

Frank Burrows

Vice President of Corporate Strategy
William C. Taylor

William C. Taylor

President & COO

MiMedx Group Office Locations

MiMedx Group has an office in Marietta
Marietta, US (HQ)
1775 West Oak Commons Ct. NE
Show all (1)

MiMedx Group Financials and Metrics

MiMedx Group Financials

MiMedx Group's revenue was reported to be $245 m in FY, 2016

Revenue (Q3, 2017)

84.6 m

Gross profit (Q3, 2017)

75 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

17.5 m

EBIT (Q3, 2017)

8.8 m

Market capitalization (16-Feb-2018)

305.5 m

Cash (30-Sep-2017)

36.5 m
MiMedx Group's current market capitalization is $305.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


59.2 m118.2 m187.3 m245 m

Revenue growth, %


Cost of goods sold

9.3 m12.7 m20.2 m32.4 m

Gross profit

49.9 m105.6 m167.1 m212.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


16.1 m19.6 m25.6 m33.5 m40.8 m45.7 m49 m53.4 m57.3 m64.4 m72.6 m76.4 m84.6 m

Cost of goods sold

2.1 m3 m2.7 m3.3 m5.1 m5.1 m5 m7.9 m7.4 m8 m8.7 m8.6 m9.6 m

Gross profit

14 m16.6 m22.8 m30.2 m35.6 m40.6 m44 m45.4 m49.9 m56.4 m63.9 m67.8 m75 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


44.1 m46.6 m28.5 m34.4 m

Accounts Receivable

16.1 m26.7 m53.8 m67.2 m


5.1 m1.5 m3.6 m17.8 m

Current Assets

65.4 m85.7 m96.3 m126.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


6.1 m43 m39.2 m47.3 m38.7 m38.6 m41.1 m15.1 m23.8 m18.3 m30.9 m47.5 m36.5 m

Accounts Receivable

13.7 m19 m20.5 m23.3 m31 m39.4 m46.8 m53.9 m54.9 m63.4 m66.8 m60.7 m59.6 m


4.5 m3.6 m4.2 m4.7 m4.2 m3.9 m5.7 m18 m17.2 m18.3 m16.1 m15 m10.4 m

Current Assets

25.8 m67.9 m66.3 m77.3 m82.3 m91.8 m102.7 m95.2 m101.8 m106.3 m121.9 m132.5 m114.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.1 m)6.2 m29.4 m12 m

Depreciation and Amortization

1.1 m928 k933 k2.1 m

Accounts Receivable

(8.4 m)(11 m)(27 m)(11.4 m)


(858 k)(203 k)(2.3 m)(2.8 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(307.1 k)(922.1 k)(390.2 k)3.7 m4.1 m5.4 m6.6 m1.2 m2 m3.3 m4.3 m

Depreciation and Amortization

232 k232.1 k233 k233 k234 k810 k447 k631 k526 k

Accounts Receivable

20.5 m23.3 m31 m39.4 m46.8 m53.9 m54.9 m63.4 m66.8 m

Accounts Payable

2.4 m2.8 m5.4 m5.6 m7.2 m13.1 m9.7 m11.2 m10.9 m
USDY, 2017


122.6 k

Financial Leverage

1.3 x
Show all financial metrics

MiMedx Group Operating Metrics

MiMedx Group's Patent Applications was reported to be 110 in FY, 2016
FY, 2016

Patents (US)


Patent Applications

Show all operating metrics

MiMedx Group Market Value History

MiMedx Group Revenue Breakdown

MiMedx Group's Web-traffic and Trends

MiMedx Group Online and Social Media Presence

MiMedx Group Company Life and Culture

You may also be interested in